Department of Dermatology and Center for Chronic Pruritus, University Hospital Münster, Von- Esmarch-Str. 58, DE-48149 Münster, Germany. E-mail:
Acta Derm Venereol. 2021 Feb 17;101(2):adv00403. doi: 10.2340/00015555-3726.
Chronic nodular prurigo is characterized by recalcitrant itch. Patient perspectives on therapeutic goals, satisfaction with therapy and efficacy of therapeutic regimens for this condition are unknown. This questionnaire study examined these issues in 406 patients with chronic nodular prurigo from 15 European dermatological centres. Improvements in itch, skin lesions and sleep were the most important goals. Emollients, topical corticosteroids and antihistamines were the most frequently used treatments, while a minority of patients were prescribed potent medications, such as systemic immunosuppressants and gabapentinoids. Most patients were not satisfied with their previous therapy (56.8%), while 9.8% did not receive any therapy despite having active disease. A substantial number of respondents (28.7%) considered none of the therapeutic options effective. Although chronic nodular prurigo is a severe disease, most patients were not treated with potent systemic drugs, which may contribute to the high levels of dissatisfaction and disbelief in available therapies. Specific guidelines for chronic nodular prurigo and the development of novel therapies are necessary to improve care.
慢性结节性痒疹的特征为顽固瘙痒。患者对该疾病治疗目标、治疗满意度和治疗方案疗效的看法尚不清楚。本问卷调查研究在来自 15 个欧洲皮肤科中心的 406 例慢性结节性痒疹患者中调查了这些问题。瘙痒、皮肤损伤和睡眠改善是最重要的目标。保湿剂、局部皮质类固醇和抗组胺药是最常使用的治疗方法，而少数患者被开处强效药物，如全身性免疫抑制剂和加巴喷丁类药物。大多数患者对其先前的治疗不满意（56.8%），而尽管疾病活跃，但仍有 9.8%的患者未接受任何治疗。相当数量的受访者（28.7%）认为没有任何治疗方法有效。尽管慢性结节性痒疹是一种严重的疾病，但大多数患者未接受强效全身药物治疗，这可能导致高比例的治疗不满和对现有治疗方法的怀疑。需要制定慢性结节性痒疹的具体指南和开发新的治疗方法，以改善治疗。
